

# The Global Arthritic Therapeutic Market: A Comprehensive Overview and Future Outlook

PORTLAND, OREGON, UNITED STATES, March 11, 2025 /EINPresswire.com/ -- The global [arthritic therapeutic market](#) is experiencing remarkable growth, fueled by an aging population, rising arthritis prevalence, and advancements in biologic and biosimilar therapies. In 2022, the market was valued at \$79.5 billion and is projected to reach \$136.1 billion by 2032, expanding at a CAGR of 5.5% from 2023 to 2032. As demand for innovative treatments increases, stakeholders must navigate key drivers, challenges, and opportunities to remain competitive in this evolving landscape.



Get a Sample Copy of this Report: <https://www.alliedmarketresearch.com/request-sample/2571>

## Key Market Drivers

### 1. Aging Population and Increasing Arthritis Cases

- The global geriatric population is expected to reach 1.4 billion people aged 60+ by 2030 (WHO).
- Arthritis prevalence rises with age, particularly for osteoarthritis and rheumatoid arthritis.
- In the U.S., 53.2 million people are diagnosed with arthritis, with a higher incidence among women.

### 2. Advances in Biologics and Biosimilars

- Biologics targeting specific inflammatory pathways are the fastest-growing segment.
- Biosimilars offer cost-effective alternatives without compromising therapeutic efficacy.
- Pharmaceutical giants like AbbVie, Pfizer, and Novartis are heavily investing in biosimilar R&D.

### 3. Expanding Healthcare Infrastructure

- Improved diagnostic capabilities enable early detection and better arthritis management.
- Government and private sector investments are enhancing healthcare access, particularly in emerging markets.

### 4. Lifestyle and Obesity-Driven Arthritis Cases

- Rising obesity and sedentary lifestyles contribute to arthritis incidence.
- This trend is driving demand for both pharmacological and non-pharmacological interventions.

## Market Challenges

### 1. Competition from Alternative Therapies

- Patients are increasingly opting for herbal remedies, acupuncture, and dietary modifications.
- This trend poses a challenge to traditional medical therapies.

### 2. Awareness and Diagnosis Gaps

- Delayed diagnosis due to lack of awareness hinders timely treatment.
- Public health campaigns and improved medical training are essential for overcoming this barrier.

### 3. Economic Constraints and Affordability

- Recessions and financial instability reduce healthcare spending, affecting access to expensive biologics.
- Regulatory approvals for biosimilars are helping mitigate cost-related challenges.

## Market Segmentation and Growth Prospects

### By Product Type

- Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Continue to dominate due to their affordability and widespread use.
- Biologics: Expected to witness the fastest CAGR, driven by superior efficacy.
- Disease-Modifying Anti-Rheumatic Drugs (DMARDs): Remain crucial for managing inflammatory arthritis conditions.

### By Application

- Rheumatoid Arthritis: The largest segment, owing to high prevalence and demand for novel therapies.
- Osteoarthritis: Projected to grow rapidly due to aging demographics and obesity trends.
- Psoriatic Arthritis & Ankylosing Spondylitis: Gaining traction with targeted biologic treatments.

### By Region

- North America: Leads the market, driven by advanced healthcare infrastructure and strong R&D investments.
- Asia-Pacific: Expected to grow at the highest CAGR due to economic growth, healthcare advancements, and increasing arthritis cases.
- Europe & LAMEA: Steady expansion, supported by rising adoption of biologics and biosimilars.

## Competitive Landscape and Recent Developments

The arthritic therapeutic market is highly competitive, with key players focusing on innovation, acquisitions, and product launches.

## Recent Milestones

- Oct 2023: Novartis secured FDA approval for an intravenous formulation of Cosentyx for

psoriatic arthritis and ankylosing spondylitis.

- Jan 2022: AbbVie's SKYRIZI gained approval for active psoriatic arthritis, expanding its applications.
- July 2020: Johnson & Johnson's TREMFYA was approved for adult patients with active psoriatic arthritis.

Future Outlook: What Lies Ahead?

Market Expansion Trends

- Increasing use of biologics and biosimilars will drive future revenue growth.
- Emerging markets will see a surge in affordable therapeutic options.
- Advancements in precision medicine will enable personalized treatment plans.

Challenges to Address

- Ensuring affordable treatment access for all patient demographics.
- Competing with alternative therapies in an increasingly diverse healthcare landscape.
- Overcoming regulatory hurdles to expedite biosimilar approvals globally.

Key Takeaways

- The global arthritic therapeutic market will grow from \$79.5 billion (2022) to \$136.1 billion (2032) at a 5.5% CAGR.
- Biologics are the fastest-growing segment, while rheumatoid arthritis remains the largest application sector.
- North America dominates, but Asia-Pacific is the fastest-growing region.
- Leading pharmaceutical companies are investing in biosimilars, innovative drugs, and strategic mergers.
- The future of arthritis treatment depends on cost-effective biologics, precision medicine, and expanded healthcare accessibility.

As the global arthritis burden increases, advancements in therapeutics and healthcare innovation will be crucial in ensuring better patient outcomes and quality of life.

Enquire Before Buying: <https://www.alliedmarketresearch.com/purchase-enquiry/2571>

David Correa

Allied Market Research

+15038946022 ext.

[email us here](#)

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

[YouTube](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/792843523>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.